comprising (i) an oil-in-water emulsion and (ii) a drug dissolved in the emulsion, wherein the oil phase comprises a hydroxylated oil and wherein the drug is for systemic delivery and is selected from the group consisting of an analgesic agent, a drug for the treatment of Parkinson's disease, a drug for the treatment of impotence, and a non-steroidal anti-inflammatory drug, but wherein the drug is not a cannabinoid.

A2

2. (Amended) A composition adapted for nasal administration comprising (i) a oil-in-water emulsion and (ii) a drug dissolved in the emulsion, wherein the oil phase comprises a hydroxylated oil and wherein the drug is for systemic delivery and is selected from the group consisting of an analgesic agent, a drug for the treatment of Parkinson's disease, a drug for the treatment of impotence and a non-steroidal anti-inflammatory drug, but wherein the drug is not a cannabinoid, for use in medicine.

5. (Amended) A composition according to Claim 1, wherein the non-steroidal anti-inflammatory drug is flurbiprofen.

A3

6. (Amended) A composition according to Claim 1, wherein the non-steroidal anti-inflammatory drug is ibuprofen.

7. (Amended) A composition according to Claim 1, wherein the non-steroidal anti-inflammatory drug is a COX-1 or COX-2 inhibitor.

10. (Amended) A method for the treatment of pain which comprises delivering an oil-in-water emulsion containing a systemically active drug by the nasal route, wherein the drug is not a cannabinoid.

A4

11. (Amended) A method according to Claim 10, wherein the drug is a non-steroidal anti-inflammatory drug.

REMARKS

Claims 1-11 are pending in the application. Claims 1, 2, 5, 6, 7, 10, and 11 have been amended to render them more fully compliant with formal requirements. No new matter is added by these amendments. A marked-up version of the claims, showing the amendments